- Home
- ZNTL vs IDR Comparison
ZNTL vs IDR Comparison
Compare ZNTL & IDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- IDR
- Stock Information
- Founded
- ZNTL 2014
- IDR 1996
- Country
- ZNTL United States
- IDR United States
- Employees
- ZNTL N/A
- IDR N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- IDR Precious Metals
- Sector
- ZNTL Health Care
- IDR Basic Materials
- Exchange
- ZNTL Nasdaq
- IDR Nasdaq
- Market Cap
- ZNTL 137.9M
- IDR 154.1M
- IPO Year
- ZNTL 2020
- IDR N/A
- Fundamental
- Price
- ZNTL $1.63
- IDR $14.31
- Analyst Decision
- ZNTL Buy
- IDR Strong Buy
- Analyst Count
- ZNTL 8
- IDR 1
- Target Price
- ZNTL $8.53
- IDR $14.00
- AVG Volume (30 Days)
- ZNTL 852.5K
- IDR 165.5K
- Earning Date
- ZNTL 03-26-2025
- IDR 05-05-2025
- Dividend Yield
- ZNTL N/A
- IDR N/A
- EPS Growth
- ZNTL N/A
- IDR 344.26
- EPS
- ZNTL N/A
- IDR 0.67
- Revenue
- ZNTL $67,425,000.00
- IDR $25,765,373.00
- Revenue This Year
- ZNTL N/A
- IDR $86.37
- Revenue Next Year
- ZNTL N/A
- IDR $11.11
- P/E Ratio
- ZNTL N/A
- IDR $21.37
- Revenue Growth
- ZNTL N/A
- IDR 64.94
- 52 Week Low
- ZNTL $1.58
- IDR $7.59
- 52 Week High
- ZNTL $16.27
- IDR $18.35
- Technical
- Relative Strength Index (RSI)
- ZNTL 36.50
- IDR 62.44
- Support Level
- ZNTL $1.78
- IDR $13.20
- Resistance Level
- ZNTL $2.02
- IDR $14.22
- Average True Range (ATR)
- ZNTL 0.15
- IDR 0.79
- MACD
- ZNTL -0.00
- IDR 0.18
- Stochastic Oscillator
- ZNTL 3.53
- IDR 97.19
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.